Lexicon Pharmaceuticals, Inc.
LXRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001062822
No open-market purchases or sales by Lexicon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 149 institutions reported holding it in 13F filings for Q2 2026, worth $875.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +13 vs. previous quarter
- 149
- 13F valueReported value at the end of Q2 2026
- $875.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LXRX, Q2 2026
No superinvestor reported holding LXRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lexicon Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Debbane RaymondDirector | PPurchase | +2.00K | $1.49 | +$2.98K | +0.1%1.91M after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Debbane RaymondDirector | PPurchase | +100.0K | $1.47 | +$147.0K | +5.5%1.90M after | |
| Feb 23, 2026 (view filing) | Feb 19-20 | 4 days | Debbane RaymondDirector | PPurchase | +150.0K | $1.47 | +$220.0K | +9.1%1.80M after | 2 lots |
| Feb 18, 2026 (view filing) | Feb 13-18 | 5 days | Debbane RaymondDirector | PPurchase | +268.5K | $1.31 | +$353.1K | +19.4%1.65M after | 3 lots |
| Feb 4, 2026 (view filing)4:25 PM ET | Feb 2 | 2 days | Debbane Raymond and 8 othersDirector | PPurchase | +1.54M | $1.30 | +$2.00M | New position1.54M after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Coats LonnelChief Executive Officer | PPurchase | +90.0K | $1.05 | +$94.5K | +10.9%914.4K after | |
| Nov 14, 2023 (view filing) | Nov 13 | 1 day | Amouyal PhilippeDirector | PPurchase | +200.0K | $1.01 | +$202.0K | +495.9%240.3K after | |
| Nov 13, 2023 (view filing) | Nov 10 | 3 days | Coats LonnelChief Executive Officer | PPurchase | +10.0K | $1.01 | +$10.1K | +1.2%824.4K after | |
| Oct 12, 2023 (view filing) | Oct 10-12 | 2 days | Debbane RaymondDirector | PPurchase | +1.00M | $1.10 | +$1.10M | +293.4%1.34M after | 3 lots |
| Sep 14, 2023 (view filing) | Sep 14 | Same day | Wade Jeffrey LPresident and CFO | PPurchase | +10.0K | $1.38 | +$13.8K | +3.9%264.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lexicon Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 175,156,062 | $420.4M | 45.15% | +20,421,735+13.2% | Added |
| FMR LLC | 51,782,045 | $124.3M | 0.01% | +6,725,707+14.9% | Added |
| Siren, L.L.C. | 44,303,518 | $106.3M | 2.16% | 00.0% | Unchanged |
| Sessa Capital IM, L.P. | 18,960,836 | $45.5M | 0.79% | +1,047,875+5.8% | Added |
| BlackRock, Inc. | 17,348,741 | $41.6M | 0.00% | +14,026,522+422.2% | Added |
| Vanguard Capital Management LLC | 9,901,208 | $23.8M | 0.00% | +382,041+4.0% | Added |
| Point72 Asset Management, L.P. | 8,251,325 | $19.8M | 0.03% | +436,719+5.6% | Added |
| Geode Capital Management, LLC | 6,244,372 | $15.0M | 0.00% | +3,075,261+97.0% | Added |
| State Street Corp | 4,917,769 | $11.8M | 0.00% | +3,953,731+410.1% | Added |
| Vanguard Portfolio Management LLC | 2,357,749 | $5.66M | 0.00% | +1,811,149+331.3% | Added |